Live Breaking News & Updates on ஜூலி சீடல்|Page 4

Stay updated with breaking news from ஜூலி சீடல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

GT Biopharma to Host Interim G - GuruFocus.com

GT Biopharma to Host Interim G - GuruFocus.com
gurufocus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gurufocus.com Daily Mail and Mail on Sunday newspapers.

Julie Seidel , Jeffreys Miller , David Castaneda , Beverly Hills , Susan Roush , Exchange Commission , Prnewswire Gt Biopharma Inc , Stern Investor Relations Inc , Source Gt Biopharma Inc , University Of Minnesota , Gt Biopharma Inc , Natural Killer , Interim Results , Clinical Trial , High Risk Myelodysplastic Syndromes , Relapsed Acute Myeloid Leukemia , Phasei Portion , Trial Design , Toll Free , Access Code , Securities Act , Investor Relations , ஜூலி சீடல் , ஜெஃப்ரீஸ் மில்லர் , டேவிட் கஷ்டனேடா , பெவர்லி மலைகள் ,

Investegate |4d Pharma PLC Announcements | 4d Pharma PLC: Presentation of Blautix IBS Phase II at DDW 2021

4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at Digestive Disease Week (DDW) 2021

Leeds, UK, May 17, 2021
, - 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that it will present data from its Phase II study of single strain LBP Blautix® in patients with irritable bowel syndrome (IBS) subtypes IBS-C and IBS-D in a poster session at Digestive Disease Week (DDW) 2021, taking place virtually May 21-23, 2021.

Presentation Title ....

United Kingdom , United States , Julie Seidel , Biotherapeutic Blautix , Eamonn Quigley , Dominic Wilson Phil Walker , Bryan Garnier Co , Merck Co Inc , Division Of Gastroenterology , Stern Investor Relations Inc , Present Additional Data , Irritable Bowel Syndrome , Digestive Disease Week , Joint Broker , Iqra Amin , James Fischer , Corporate Finance , Corporate Broking , Investor Relations , Investegate Announcements , Investegate Company Announcements , 4d Pharma Plc , Egulatory News Service , Egulatory News Service And Regulatory , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் ,

GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE(TM) Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE(TM) Product Candidates

GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE(TM) Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE(TM) Product Candidates
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Julie Seidel , Anthonyj Cataldo , David Castaneda Susan Roush , Beverly Hills , Exchange Commission , Stern Investor Relations Inc , National Cancer Institute , University Of Minnesota , Gt Biopharma Inc , Bone Marrow Blast Levels , Allogenic Cell Therapy , Chief Executive , Securities Act , Investor Relations , Media Relations , ஒன்றுபட்டது மாநிலங்களில் , ஜூலி சீடல் , பெவர்லி மலைகள் , பரிமாற்றம் தரகு , கடுமையான முதலீட்டாளர் உறவுகள் இன்க் , தேசிய புற்றுநோய் நிறுவனம் , பல்கலைக்கழகம் ஆஃப் மினசோட்டா , எலும்பு மஜ்ஜை குண்டு வெடிப்பு நிலைகள் , தலைமை நிர்வாகி , பத்திரங்கள் நாடகம் ,

GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE™ Product Candidates

Share this article
Share this article
BEVERLY HILLS, Calif., May 12, 2021 /PRNewswire/ GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company s proprietary NK cell engager (TriKE™) protein biologic technology platform, is pleased to provide an update concerning the commencement of the GTB-3550 TriKE™ monotherapy Phase 2 clinical trial, and certain of its solid tumor targeting TriKE™ product candidates.
Highlights to date from patients treated with GTB-3550 TriKE™ in the dose escalation Phase 1 clinical trial for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML):
Up to 63.7% Reduction in Bone Marrow Blast Levels seen in some patients. ....

United States , Julie Seidel , Anthonyj Cataldo , David Castaneda , Beverly Hills , Susan Roush , Stern Investor Relations Inc , National Cancer Institute , Source Gt Biopharma Inc , Exchange Commission , University Of Minnesota , Gt Biopharma Inc , Bone Marrow Blast Levels , Allogenic Cell Therapy , Chief Executive , Securities Act , Investor Relations , Media Relations , Gt Biopharma , ஒன்றுபட்டது மாநிலங்களில் , ஜூலி சீடல் , டேவிட் கஷ்டனேடா , பெவர்லி மலைகள் , சூசன் ரஷ் , கடுமையான முதலீட்டாளர் உறவுகள் இன்க் , தேசிய புற்றுநோய் நிறுவனம் ,

Investegate |Faron Pharma. Oy Announcements | Faron Pharma. Oy: Grant of options

Investegate announcements from Faron Pharma. Oy, Grant of options ....

Landskapet Sodra Savolax , Julie Seidel , Mark Rogers , Poulos John , Whitaker Anne , Markku Jalkanen , Sandy Jamieson , Lindsey Neville , Jalkanen Juho , Knowles Jonathan , Christopher Golden , Jalkanen Markku , Juha Karttunen , Brown Gregory , David Daley , Curiel Tyler , Jo Turner , Zambeletti Leopoldo , Mandelin Jami , Lahtinen Maria , Armstrong Frank , Mary Jane Elliott , Jalkanen Sirpa , Us Air , Faron Pharmaceuticals Oy , Peel Hunt ,